NH DHHS: Don’t Eat, Sell Diamond Shruumz Chocolate Bars, Cones, and Gummies

Print More

From the FDA website

Concord, NH – The New Hampshire Department of Health and Human Services (DHHS), Division of Public Health Services (DPHS) is advising consumers not to eat, sell, or serve any Diamond Shruumz Microdosing Chocolate Bars, Infused Cones, or Micro Dose and Macro Dose gummies, and instead to throw them away. The U.S. Food and Drug Administration (FDA) is investigating a series of illnesses associated with the products, which are labeled as containing a proprietary blend of mushrooms, including reishi and lion’s mane.

Diamond Shruumz products can be purchased online or at a variety of retail locations nationwide, including smoke and vape shops or places that sell hemp-derived or CBD products. The impacted products were distributed to stores in New Hampshire.

Retailers should not sell or distribute any of these products. Instead, please hold all Diamond Shruumz products until the FDA provides further direction on how to dispose of or safely return them.

“As people in multiple states have become ill with a variety of severe symptoms after eating these products, we are advising Granite Staters to avoid consuming them,” said Iain Watt, DPHS Director. “We will continue to monitor information from our federal partners about this ongoing investigation.”

Since May 28, 2024, the FDA has received a total of 39 illness complaints associated with consuming certain Diamond Shruumz products. People who became ill after eating the products reported a variety of severe symptoms, including seizures, central nervous system depression (loss of consciousness, confusion, sleepiness), agitation, abnormal heart rates, high or low blood pressure, nausea, and vomiting. There have been no illnesses reported in New Hampshire.

Those who become ill after consuming these products should seek medical treatment or call the Poison Help Line at 1-800-222-1222. Healthcare providers with questions or concerns can contact DHHS by calling 603-271-4496.

For updates about this investigation, please visit the FDA website.

Comments are closed.